A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice

Rob Tierney, Toru Nakai, Christopher J. Parkins, Patrizia Caposio, Neil F. Fairweather, Dorothea Sesardic, Michael A. Jarvis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The current commercially available vaccine used to prevent tetanus disease following infection with the anaerobic bacterium . Clostridium tetani is safe and effective. However, tetanus remains a major source of mortality in developing countries. In 2008, neonatal tetanus was estimated to have caused >59,000 deaths, accounting for 1% of worldwide infant mortality, primarily in poorer nations. The cost of multiple vaccine doses administered by injection necessary to achieve protective levels of anti-tetanus toxoid antibodies is the primary reason for low vaccine coverage. Herein, we show that a novel vaccine strategy using a cytomegalovirus (CMV)-based vaccine platform induces protective levels of anti-tetanus antibodies that are durable (lasting >13 months) in mice following only a single dose. This study demonstrates the ability of a 'single-dose' CMV-based vaccine strategy to induce durable protection, and supports the potential for a tetanus vaccine based on CMV to impact the incidence of tetanus in developing countries.

Original languageEnglish (US)
Pages (from-to)3047-3052
Number of pages6
JournalVaccine
Volume30
Issue number20
DOIs
StatePublished - Apr 26 2012

Fingerprint

Cytomegalovirus Vaccines
Tetanus Toxin
Cytomegalovirus
tetanus
Tetanus
toxins
vaccines
Vaccines
antibodies
Antibodies
mice
dosage
Tetanus Toxoid
Developing Countries
Clostridium tetani
developing countries
Anaerobic Bacteria
Infant Mortality
infant mortality
application coverage

Keywords

  • Antibody
  • Cytomegalovirus-based vaccine
  • Mice
  • Neglected tropical disease
  • Tetanus

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice. / Tierney, Rob; Nakai, Toru; Parkins, Christopher J.; Caposio, Patrizia; Fairweather, Neil F.; Sesardic, Dorothea; Jarvis, Michael A.

In: Vaccine, Vol. 30, No. 20, 26.04.2012, p. 3047-3052.

Research output: Contribution to journalArticle

Tierney, Rob ; Nakai, Toru ; Parkins, Christopher J. ; Caposio, Patrizia ; Fairweather, Neil F. ; Sesardic, Dorothea ; Jarvis, Michael A. / A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice. In: Vaccine. 2012 ; Vol. 30, No. 20. pp. 3047-3052.
@article{09cd860a809a4fd295d23334b4ac66e5,
title = "A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice",
abstract = "The current commercially available vaccine used to prevent tetanus disease following infection with the anaerobic bacterium . Clostridium tetani is safe and effective. However, tetanus remains a major source of mortality in developing countries. In 2008, neonatal tetanus was estimated to have caused >59,000 deaths, accounting for 1{\%} of worldwide infant mortality, primarily in poorer nations. The cost of multiple vaccine doses administered by injection necessary to achieve protective levels of anti-tetanus toxoid antibodies is the primary reason for low vaccine coverage. Herein, we show that a novel vaccine strategy using a cytomegalovirus (CMV)-based vaccine platform induces protective levels of anti-tetanus antibodies that are durable (lasting >13 months) in mice following only a single dose. This study demonstrates the ability of a 'single-dose' CMV-based vaccine strategy to induce durable protection, and supports the potential for a tetanus vaccine based on CMV to impact the incidence of tetanus in developing countries.",
keywords = "Antibody, Cytomegalovirus-based vaccine, Mice, Neglected tropical disease, Tetanus",
author = "Rob Tierney and Toru Nakai and Parkins, {Christopher J.} and Patrizia Caposio and Fairweather, {Neil F.} and Dorothea Sesardic and Jarvis, {Michael A.}",
year = "2012",
month = "4",
day = "26",
doi = "10.1016/j.vaccine.2012.02.043",
language = "English (US)",
volume = "30",
pages = "3047--3052",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "20",

}

TY - JOUR

T1 - A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice

AU - Tierney, Rob

AU - Nakai, Toru

AU - Parkins, Christopher J.

AU - Caposio, Patrizia

AU - Fairweather, Neil F.

AU - Sesardic, Dorothea

AU - Jarvis, Michael A.

PY - 2012/4/26

Y1 - 2012/4/26

N2 - The current commercially available vaccine used to prevent tetanus disease following infection with the anaerobic bacterium . Clostridium tetani is safe and effective. However, tetanus remains a major source of mortality in developing countries. In 2008, neonatal tetanus was estimated to have caused >59,000 deaths, accounting for 1% of worldwide infant mortality, primarily in poorer nations. The cost of multiple vaccine doses administered by injection necessary to achieve protective levels of anti-tetanus toxoid antibodies is the primary reason for low vaccine coverage. Herein, we show that a novel vaccine strategy using a cytomegalovirus (CMV)-based vaccine platform induces protective levels of anti-tetanus antibodies that are durable (lasting >13 months) in mice following only a single dose. This study demonstrates the ability of a 'single-dose' CMV-based vaccine strategy to induce durable protection, and supports the potential for a tetanus vaccine based on CMV to impact the incidence of tetanus in developing countries.

AB - The current commercially available vaccine used to prevent tetanus disease following infection with the anaerobic bacterium . Clostridium tetani is safe and effective. However, tetanus remains a major source of mortality in developing countries. In 2008, neonatal tetanus was estimated to have caused >59,000 deaths, accounting for 1% of worldwide infant mortality, primarily in poorer nations. The cost of multiple vaccine doses administered by injection necessary to achieve protective levels of anti-tetanus toxoid antibodies is the primary reason for low vaccine coverage. Herein, we show that a novel vaccine strategy using a cytomegalovirus (CMV)-based vaccine platform induces protective levels of anti-tetanus antibodies that are durable (lasting >13 months) in mice following only a single dose. This study demonstrates the ability of a 'single-dose' CMV-based vaccine strategy to induce durable protection, and supports the potential for a tetanus vaccine based on CMV to impact the incidence of tetanus in developing countries.

KW - Antibody

KW - Cytomegalovirus-based vaccine

KW - Mice

KW - Neglected tropical disease

KW - Tetanus

UR - http://www.scopus.com/inward/record.url?scp=84859431799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859431799&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.02.043

DO - 10.1016/j.vaccine.2012.02.043

M3 - Article

C2 - 22414558

AN - SCOPUS:84859431799

VL - 30

SP - 3047

EP - 3052

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 20

ER -